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Management of acute organophosphorus pesticide poisoning
Michael Eddleston, Nick A Buckley, Peter Eyer, Andrew H Dawson
Organophosphorus pesticide self-poisoning is an important clinical problem in rural regions of the developing world, 
and kills an estimated 200 000 people every year. Unintentional poisoning kills far fewer people but is a problem in 
places where highly toxic organophosphorus pesticides are available. Medical management is diﬃ  cult, with case fatality 
generally more than 15%. We describe the limited evidence that can guide therapy and the factors that should be 
considered when designing further clinical studies. 50 years after ﬁ rst use, we still do not know how the core 
treatments—atropine, oximes, and diazepam—should best be given. Important constraints in the collection of useful 
data have included the late recognition of great variability in activity and action of the individual pesticides, and the 
care needed cholinesterase assays for results to be comparable between studies. However, consensus suggests that 
early resuscitation with atropine, oxygen, respiratory support, and ﬂ uids is needed to improve oxygen delivery to 
tissues. The role of oximes is not completely clear; they might beneﬁ t only patients poisoned by speciﬁ c pesticides or 
patients with moderate poisoning. Small studies suggest beneﬁ t from new treatments such as magnesium sulphate, 
but much larger trials are needed. Gastric lavage could have a role but should only be undertaken once the patient is 
stable. Randomised controlled trials are underway in rural Asia to assess the eﬀ ectiveness of these therapies. However, 
some organophosphorus pesticides might prove very diﬃ  cult to treat with current therapies, such that bans on 
particular pesticides could be the only method to substantially reduce the case fatality after poisoning. Improved 
medical management of organophosphorus poisoning should result in a reduction in worldwide deaths from suicide.
Organophosphorus pesticide self-poisoning is a major 
clinical and public-health problem across much of rural 
Asia.1–3 Of the estimated 500 000 deaths from self-harm 
in the region each year,4 about 60% are due to pesticide 
poisoning.3 Many studies estimate that organophosphorus 
pesticides are responsible for around two-thirds of these 
deaths5—a total of 200 000 a year.3 Deaths from 
unintentional organophosphorus poisoning are less 
common than those from intentional poisoning6 and 
seem to be more common in regions where highly toxic 
organophosphorus pesticides (WHO Class I toxicity) are 
available.7,8 In a large cohort of Sri Lankan patients 
poisoned with WHO Class II organophosphorus 
pesticides,9,10 no deaths resulted from unintentional 
poisoning (Eddleston M, unpublished).
Hospitals in rural areas bear the brunt of this problem, 
seeing many hundreds of patients poisoned by 
pesticides each year, with a case fatality of 15–30%.5,11 
Unfortunately, these hospitals are frequently not 
adequately staﬀ ed or equipped to deal with these very 
sick patients—intensive care beds and ventilators are in 
short supply—so even unconscious patients are 
managed on open wards (ﬁ gure 1). Furthermore, the 
evidence for treatment is weak12 and if evidence of 
beneﬁ t does exist for particular antidotes, they are 
poorly used13–15 or unavailable.3
Improved medical management and provision of 
antidotes and intensive care beds, together with bans on 
the most toxic pesticides,16 should reduce the case fatality 
for self-poisoning and noticeably reduce the number of 
deaths from self-harm in rural Asia.3,12
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Search strategy and selection criteria
We searched for relevant studies by searching PubMed 
(1960–2006), Embase (1974–2006), UK National Research 
Register, Cochrane Injuries Group Specialised Register, 
Clinicaltrials.gov and the Cochrane databases (all until 
Dec 2006) for “organophosphorus”, ”organophosphate”, or 
”organic phosphorus” and ”poisoning” or ”toxicity”. We did 
not limit the search by language; however, we had limited 
ability to translate papers from China where many studies 
have been done. Translation of Chinese papers was therefore 
ordered according to relevance, established by review of 
English abstracts. We also used information from our 
continuing studies in Sri Lanka that have recruited more than 
2000 patients poisoned with organophosphate, and from 
discussions with clinicians seeing such patients across Asia.
Figure 1: Management of a patient with severe organophosphorus poisoning in a Sri Lankan district hospital
The absence of intensive-care beds and ventilators means that unconscious patients are frequently intubated and 
ventilated on the open ward. This ﬁ gure is reproduced with permission from the corresponding author.
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Pathophysiology 
Organophosphorus pesticides inhibit esterase en zymes, 
especially acetylcholinesterase (EC 3.1.1.7) in synapses 
and on red-cell membranes, and butyrylcholin es-
terase (EC 3.1.1.8) in plasma.17 Although acute 
butyrylcholinesterase inhibition does not seem to cause 
clinical features, acetylcholinesterase inhibition results 
in accumulation of acetylcholine and overstimulation of 
acetylcholine receptors in synapses of the autonomic 
nervous system, CNS, and neuromuscular junctions.17 
The subsequent autonomic, CNS, and neuromuscular 
features of organophosphorus poisoning are well known 
(panel 1).
Patients can suddenly develop peripheral respiratory 
failure while conscious after seemingly recovering from 
cholinergic crisis, which is termed type II respiratory 
failure or intermediate syndrome.21,22 This syndrome is an 
important cause of death in patients who have been 
resuscitated and stabilised on admission to hospital. 
Diagnosis is made on the basis of clinical suspicion, the 
characteristic clinical signs, smell of pesticides or solvents, 
and reduced butyrylcholinesterase or acetylcholinesterase 
activity in the blood.17 Patients with severe organophosphorus 
poisoning typically present with pinpoint pupils, excessive 
sweating, reduced consciousness, and poor respiration. 
The major diﬀ erential diagnosis is carbamate poisoning, 
which is clinically indistinguishable.18
Cholinesterase assays
Diagnosis of organophosphorus poisoning should ideally 
be conﬁ rmed with an assay to measure butyryl-
cholinesterase activity in plasma (or acetylcholinesterase 
in whole blood).17 However, the results of such assays are 
rarely available in time to aﬀ ect clinical decisionmaking. 
Their importance is for guidance of clinical research; 
under standing of their limitations is essential for 
Panel 1: Clinical features of organophosphorus pesticide 
poisoning18–20
Features due to overstimulation of muscarinic 
acetylcholine receptors in the parasympathetic system
• Bronchospasm
• Bronchorrhoea
• Miosis
• Lachrymation
• Urination
• Diarrhoea
• Hypotension
• Bradycardia 
• Vomiting
• Salivation
Features due to overstimulation of nicotinic acetylcholine 
receptors in the sympathetic system
• Tachycardia
• Mydriasis
• Hypertension
• Sweating
Features due to overstimulation of nicotinic and 
muscarinic acetylcholine receptors in the CNS
• Confusion
• Agitation
• Coma
• Respiratory failure
Features due to overstimulation of nicotinic acetylcholine 
receptors at the neuromuscular junction
• Muscle weakness
• Paralysis
• Fasciculations
Patients usually present with features of parasympathetic overstimulation. A few might 
show signs of sympathetic stimulation, including tachycardia. However, tachycardia can 
also be caused by hypovolaemia, hypoxia, previous doses of atropine, and alcohol 
withdrawal. Respiratory failure can be due to bronchospasm, bronchorrhoea (both 
reversible with atropine), and dysfunction of neuromuscular junctions and the CNS. 
Panel 2: Drawbacks of cholinesterase activity assays23
Plasma butyrylcholinesterase assays
• Inhibition of butyrylcholinesterase, also called plasma 
cholinesterase or pseudocholinesterase, does not give 
information about clinical severity of the poisoning. Many 
organophosphorus pesticides are more potent inhibitors 
of butyrylcholinesterase than they are of 
acetylcholinesterase; butyrylcholinesterase inhibition 
might occur to a greater extent than acetylcholinesterase 
inhibition.9 Butyrylcholinesterase assays can be used to 
detect exposure to an organophosphorus or carbamate 
pesticide
• Butyrylcholinesterase is produced by the liver, and blood 
concentrations recover by about 7% of normal each day 
once the organophosphorus has been eliminated.24 Daily 
butyrylcholinesterase assays can be used to monitor when 
enzyme activity starts to rise again, since this recovery 
suggests that the organophosphorus has been eliminated 
(ﬁ gure 2)
• Variation between commercial assays can make 
comparisons between studies diﬃ  cult. The concentration 
of butyrylthiocholine varies between assays. A high 
concentration substrate (eg, 7 mM vs 1 mM) will result in 
a 30% higher measured activity and a higher background25
• Measurement of butyrylthiocholine hydrolysis in the 
absence of plasma is needed to measure non-enzymatic 
hydrolysis and hence background values. Not all 
commercial assays provide such a control. The 
background amount of spontaneous butyrylthiocholine 
hydrolysis is aﬀ ected by its concentration and pH, which 
both vary between assay kits25
• Temperature control is important, because 
butyrylcholinesterase activity increases by some 4% per 
1°C increase in temperature26
(Continues on next page)
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interpretation of studies looking at individual pesticides 
and speciﬁ c interventions.
Unfortunately, much confusion exists about the use 
and interpretation of these assays (panel 2). Some 
pesticides inhibit butyrylcholinesterase more eﬀ ectively 
than they inhibit acetylcholinesterase.9 Butyryl cholin-
esterase activity does not relate to severity of poisoning; 
however, it can be used as a sensitive marker of expo-
sure to most organophosphorus compounds or other 
cholinesterase-inhibiting compounds, and for meas-
uring organophosphorus elimination from the body 
(ﬁ gure 2).
Studies suggest that red-cell acetylcholinesterase is a 
good marker of synaptic function and atropine needs in 
patients poisoned with organophosphorus, and is 
therefore probably a good marker of severity.29,30 Patients 
with red-cell acetylcholinesterase activity of at least 
30% had normal muscle function and no need for 
atropine. By contrast, patients with less than 10% of 
normal red-cell acetylcholinesterase activity had grossly 
deranged muscle function and needed high doses of 
atropine. Acetylcholinesterase activity between these 
values was associated with moderate impairment of 
muscle function and need for atropine. 
A major drawback of acetylcholinesterase assays is that 
the interaction between organophosphorus, acetyl-
(Continued from previous page)
Red cell acetylcholinesterase assays
• These assays measure acetylcholinesterase expressed on 
the surface of red cells. Red-cell acetylcholinesterase 
inhibition is a good marker of such inhibition in synapses 
and of poisoning severity. This enzyme is measured in 
whole blood in which butyrylcholinesterase activity has 
been blocked by an inhibitor. Acetylcholinesterase is 
present at very low levels in human plasma and serum27 
• Once red-cell acetylcholinesterase has aged, it only 
recovers via erythropoeisis. Regeneration at less than 1% 
per day is therefore much slower than 
butyrylcholinesterase regeneration. The rate of 
spontaneous neuronal acetylcholinesterase recovery is 
unclear, and thus red-cell acetylcholinesterase could be a 
less useful marker of synaptic acetylcholinesterase 
activity as recovery occurs
• Reactions between acetylcholinesterase, 
organophosphorus and oximes will continue if a blood 
sample is left at room temperature after sampling. The 
measured acetylcholinesterase activity will then not 
represent the exact activity in the blood at the time of 
sampling; leaving samples for diﬀ erent times will give 
variation in assays. Blood samples must be diluted and 
cooled immediately after sampling, to stop the reactions. 
We routinely dilute by a factor of 20 at the bedside by 
mixing 200 µL of blood freshly drawn into an EDTA tube 
with 4 mL of cold saline (at 4˚C) and then place the 
sample in a freezer at −20˚C within 5 min
• Incubation of an aliquot of blood with a large quantity of 
oxime (eg, 100 µmol/L obidoxime) for 15 min before 
assay will reactivate any acetylcholinesterase that has not 
aged. Such an assay could potentially be used to establish 
whether a patient might beneﬁ t from continued oxime 
therapy or from higher doses
• Acetylcholinesterase assays are sensitive to the 
concentration of oxime and substrate, and pH. Assays 
with a low substrate concentration, pH 7·4, and 
therapeutic oxime concentrations will reduce background 
signal in the assay;23,28 however, a blank sample without 
plasma is needed to quantify the background signal
• Matrix sulfh ydryl compounds in red cells (mainly 
haemoglobin) react with Ellman’s reagent. This reaction 
should be completed by preincubation of red-cell samples 
with the reagent during temperature equilibration. A 
higher background activity will be recorded if this 
procedure is not done
Monitoring a patient’s cholinesterase status after 
organophosphate poisoning enables the veriﬁ cation of 
substantial exposure to anticholinesterase agents. In future, 
such assays could facilitate the decision about when to stop 
oxime treatment and allow cautious weaning of a patient 
from a ventilator when butyrylcholinesterase activity is 
increasing. Studies are underway to conﬁ rm the clinical 
usefulness of this approach.
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Figure 2: Use of butyrylcholinesterase recovery as a marker of organophosphorus pesticide elimination in 
(A) dimethoate and (B) fenthion poisoning 
Dimethoate is hydrophilic and rapidly excreted from the body. Plasma butyrylcholinesterase activity therefore 
begins to rise again within two days of ingestion. By contrast, fenthion is fat soluble and slowly redistributes into 
the blood after initial distribution into the fat. As a result, fenthion is detectable in the blood for many days and 
butyrylcholinesterase activity remains inhibited. 
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cholinesterase, and oximes continues if the sample is left 
at room temperature for even a few minutes (panel 2). To 
obtain reliable results, the reaction must be stopped 
immediately by cooling and dilution of the sample as 
soon as it is taken from the patient. Otherwise diﬀ erences 
of only a few minutes in the time taken to cool a sample 
will cause notable variation over repeated samples, which 
makes interpretation diﬃ  cult.
Principles of therapy
Treatment includes resuscitation of patients and giving 
oxygen, a muscarinic antagonist (usually atropine), 
ﬂ uids, and an acetylcholinesterase reactivator (an oxime 
that reactivates acetylcholinesterase by removal of the 
phosphate group) (panel 3).35 Respiratory support is given 
as necessary. Gastric decontamination should be 
considered only after the patient has been fully 
resuscitated and stabilised. Patients must be carefully 
observed after stabilisation for changes in atropine needs, 
worsening respiratory function because of intermediate 
syndrome, and recurrent cholinergic features occuring 
with fat-soluble organophosphorus.
Few randomised trials of such poisoning have been 
done; consequently the evidence base is restricted.35 Both 
atro pine and oximes were introduced into clinical practice 
rapidly in the 1950s without clinical trials.36,37 As a result, 
we do not know the ideal regimens for either therapy. Trials 
of other interventions are hindered because the best way 
to give the core treatments has not yet been determined 
and is highly variable in practice. This variability interferes 
with development of a widely accepted study protocol and 
limits the external validity of study results.
Eﬃ  cacy of treatment and outcome 
The case fatality reported by hospitals varies markedly—
from 1·85% in the Posion Control Centre of Mach Mai 
hospital, Hanoi, Vietnam to 40% in a German intensive-
care unit (Pham Due, Personal Communication).38,39 
Since so few randomised trials have been done, 
comparison of eﬀ ectiveness of therapies given in diﬀ erent 
hospitals is tempting. Unfortunately, such comparisons 
are confounded by many factors (panel 4).
In particular, although many textbooks regard 
poisoning with various organophosphorus pesticides to 
be broadly similar and equally responsive to treatment, 
diﬀ erences in chemistry have major consequences for 
treatment eﬃ  cacy.9,48 The pesticide ingested deﬁ nes how 
many patients survive to reach medical attention, how 
ill they are at admission, eﬀ ectiveness of oxime therapy, 
likelihood of recurrent cholinergic crises, or need for 
respiratory support (panel 4). Such variation reaﬃ  rms 
the importance of randomised trials to measure 
eﬀ ectiveness of treatments for speciﬁ c pesticides.
Initial stabilisation
Severe acute organophosphorus pesticide poisoning is a 
medical emergency. Treatment must ensure that the 
Panel 3: Summary of treatment20,31,32
• Check airway, breathing, and circulation. Place patient in the left lateral position, 
preferably with head lower than the feet, to reduce risk of aspiration of stomach 
contents. Provide high ﬂ ow oxygen, if available. Intubate the patient if their airway or 
breathing is compromised
• Obtain intravenous access and give 1–3 mg of atropine as a bolus, depending on 
severity. Set up an infusion of 0·9% normal saline; aim to keep the systolic blood 
pressure above 80 mm Hg and urine output above 0·5 mL/kg/h
• Record pulse rate, blood pressure, pupil size, presence of sweat, and auscultatory 
ﬁ ndings at time of ﬁ rst atropine dose
• Give pralidoxime chloride 2 g (or obidoxime 250 mg) intravenously over 20–30 min 
into a second cannula; follow with an infusion of pralidoxime 0·5–1 g/h (or obidoxime 
30 mg/hr) in 0·9% normal saline
• 5 min after giving atropine, check pulse, blood pressure, pupil size, sweat, and chest 
sounds. If no improvement has taken place, give double the original dose of atropine
• Continue to review every 5 min; give doubling doses of atropine if response is still 
absent. Once parameters have begun to improve, cease dose doubling. Similar or 
smaller doses can be used
• Give atropine boluses until the heart rate is more than 80 beats per minute, the 
systolic blood pressure is more than 80 mm Hg, and the chest is clear (appreciating 
that atropine will not clear focal areas of aspiration). Sweating stops in most cases. 
A tachycardia is not a contraindication to atropine since it can be caused by many 
factors (panel 1). The pupils will commonly dilate; however, this sign is not a useful 
endpoint for initial atropine treatment because a delay exists before maximum eﬀ ect. 
However, very dilated pupils are an indicator of atropine toxicity
• Clinical judgment is needed about additional doses of atropine if the heart rate 
and blood pressure are slightly below their targets but the chest is clear. More 
atropine at this point might not be needed. Severe hypotension might beneﬁ t from 
vasopressors. The value of vasopressors versus higher doses of atropine is not yet 
clear33,34
• Once the patient is stable, start an infusion of atropine giving every hour about 
10–20% of the total dose needed to stabilise the patient. Check the patient often to 
see if too much or too little atropine is being given. If too little is given, cholinergic 
features will re-emerge after some time.31 If too much is given, patients will become 
agitated and pyrexial, and develop absent bowel sounds and urinary retention. If this 
happens, stop the infusion and wait 30–60 min for these features to settle before 
starting again at a lower infusion rate
• Continue the oxime infusion until atropine has not been needed for 12–24 h and the 
patient has been extubated
• Continue to review respiratory function. Intubate and ventilate patients if tidal 
volume is below 5 mL/kg or vital capacity is below 15 mL/kg, or if they have apnoeic 
spells, or PaO2 is less than 8 kPa (60 mm Hg) on FIO2 of more than 60%
• Assess ﬂ exor neck strength regularly in conscious patients by asking them to lift their 
head oﬀ  the bed and hold it in that position while pressure is applied to their forehead. 
Any sign of weakness is a sign that the patient is at risk of developing peripheral 
respiratory failure (intermediate syndrome). Tidal volume should be checked every 4 h 
in such patients. Values less than 5 mL/kg suggest a need for intubation and ventilation
• Treat agitation by reviewing the dose of atropine being given and provide adequate 
sedation with benzodiazepines. Physical restraint of agitated patients in warm 
conditions risks severe hyperthermia, which is exacerbated greatly by atropine 
because it inhibits normal thermoregulatory responses, including sweating. Adequate 
sedation is therefore important
• Monitor frequently for recurring cholinergic crises due to release of fat soluble 
organophosphorus from fat stores. Such crises can occur for several days to weeks 
after ingestion of some organophosphorus. Patients with recurring cholinergic 
features will need retreatment with atropine and oxime
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patient has a patent airway and adequate breathing and 
circulation. Ideally, oxygen should be provided at the ﬁ rst 
opportunity. However, little evidence supports the 
common advice that atropine must not be given until 
oxygen is available.17,19,49,50 In hospitals that have no access 
to oxygen, atropine should be given early to patients with 
pesticide poisoning to reduce secretions and improve 
respiratory function.32 The patient should be placed in 
the left lateral position, with the neck extended. This 
position reduces risk of aspiration, helps keep the airway 
patent, and could decrease pyloric emptying and 
absorption of poison.51,52 Supportive care should include 
giving ﬂ uids and control of blood glucose.
Health-care workers are thought to be at risk of 
poisoning during initial stabilisation of patients poisoned 
with organophosphorus.53,54 A few Western hospitals have 
reported cases of such poisoning, but none have shown 
inhibition of acetylcholinesterase or butyrylcholinesterase 
in health-care workers consistent with substantial 
exposure to organophosphorus.55 Some symptoms, such 
as headaches and nausea, are possibly due to anxiety or 
exposure to the organic solvent (eg, xylene) in which the 
pesticide is mixed.55,56 
Hundreds of thousands of patients with severe 
organophosphorus poisoning are seen every year in basic 
hospitals across Asia; health-care workers take no special 
precautions and no cases of secondary poisoning have 
been reported. Reticence by hospital workers to treat 
patients poisoned with pesticides puts patients at risk. 
Guidelines recommend universal precautions, maximum 
ventilation, and frequent rotation of staﬀ , so that eﬀ ects 
of solvent and pesticide are kept to a minimum.55
Muscarinic antagonist drugs
Although atropine remains the mainstay of therapy 
worldwide,14,49 other muscarinic antagonists have been 
studied in animals.49 An important diﬀ erence between 
such drugs is their penetration into the CNS.57 
Glycopyrronium bromide and hyoscine methobromide 
do not enter the CNS, but hyoscine has excellent 
penetration; atropine enters the CNS, but not to the same 
degree as hyoscine. 
The main adverse-eﬀ ect of atropine is anticholinergic 
delirium in patients who receive too high a dose.49 Some 
physicians therefore prefer glycopyrronium to treat the 
peripheral eﬀ ects of organophosphorus without causing 
confusion. However, its poor CNS penetration suggests 
that it is ineﬀ ective at countering coma and reduced 
respiration seen in patients with the cholinergic 
syndrome. A small randomised controlled trial comparing 
glycopyrronium with atropine noted no signiﬁ cant 
diﬀ erence in mortality or ventilation rates, but it did not 
have suﬃ  cient power to detect small diﬀ erences between 
treatments.58
Hyoscine was used successfully to treat a patient with 
severe extra-pyramidal features but few peripheral signs.59 
Animal studies suggest that it is more eﬀ ective than 
Panel 4: Factors aﬀ ecting outcome in organophosphorus pesticide self-poisoning
• Toxicity: toxicity is usually rated according to the oral LD50 in rats. This scale is able to 
roughly diﬀ erentiate between very safe and very toxic pesticides—for example 
parathion (LD50 13 mg/kg,40 WHO: Class IA) is highly toxic while temephos (LD50 
8600 mg/kg,40 WHO: unlikely to cause acute hazard) has not been associated with 
deaths. However, large diﬀ erences in human toxicity have been seen after poisoning 
with organophosphates with roughly the same animal toxicity,9,11 and this 
classiﬁ cation does not account for the eﬀ ects of treatment9
• Impurities: the WHO toxicity classiﬁ cation assesses fresh pesticide from approved 
manufacturers. Pesticide storage in hot conditions can result in chemical reactions 
that have toxic products. Such a process was blamed for the death of pesticide 
sprayers using malathion in Pakistan in the late 1970s41,42 and has also been noted 
with both diazinon and dimethoate43,44
• Formulation: a pesticide’s toxicity will vary according to formulation, which diﬀ ers 
according to the organophosphorus and the place of manufacture. For example, 
malathion is available as an 80% solution in street-side pesticide stalls in Burma, but 
as a 3% powder in Sri Lanka
• Alkyl sub-groups: most pesticides have either two methyl groups attached via 
oxygen atoms to the phosphate (dimethyl organophosphorus) or two ethyl groups 
(diethyl organophosphates) (ﬁ gure 3). Acetylcholinesterase ageing is much faster 
for dimethyl poisoning than for diethyl poisoning, therefore to be eﬀ ective, oximes 
must be given quickly to patients with dimethyl poisoning (panel 5). A few 
pesticides have atypical structures, with another alkyl group (eg, propyl in 
profenofos) attached to the phosphate group via a sulphur atom. These 
organophosphorus pesticides age acetylcholinesterase even faster and oximes are 
probably not eﬀ ective
• Need for activation. Many compounds are inactive thioates (with a double-bonded 
sulphur attached to the phosphorus atom) and have to be desulphurated to make the 
active oxon, via cytochrome P450 enzymes in the gut wall and liver. The P450 3A4 
seems to be the most active enzyme when organophorus is present in high 
concentrations, as happens after self-poisoning45
• Speed of activation and of AChE inhibition. The rate of activation of thioate 
organophosphates varies between pesticides.45,46 Large variation also exists in the rate 
of acetylcholinesterase inhibition between organophosphorus pesticide oxons13
• Duration of eﬀ ect—fat solubility and half-life. Some fat soluble thioate 
organophosphorus pesticides (eg, fenthion) distribute in large amounts to fat stores 
after absorption. This seems to reduce the peak blood organophosphorus 
concentration and the early cholinergic features are usually mild. Subsequent slow 
redistribution and activation causes recurrent cholinergic features lasting days or 
weeks. Peripheral respiratory failure is common with these organophosphorus, 
probably due to continuing inhibition of acetylcholinesterase. Ageing only starts after 
acetylcholinesterase inhibition, so oximes could theoretically be beneﬁ cial for many 
days in such patients. By contrast, other organophosphorus (eg, dichlorvos) do not 
need activation, are not fat soluble, and could have a much more rapid onset of eﬀ ect 
and shorter duration of activity. Fat solubility is graded according to the Kow 
(logarithm octanol/water coeﬃ  cient): less than 1·0=not fat soluble; more than 
4·0=very fat soluble47
The above factors have important consequences for the speed of onset of 
organophosphorus poisoning after ingestion. Ingestion of an oxon organophosphorus 
that rapidly inhibits acetylcholinesterase will result in early onset of clinical features and 
respiratory arrest before presentation to hospital, increasing the risk of hypoxic brain 
damage and aspiration. The conversion of the thioate organophosphorus parathion to 
paraoxon is so fast that patients can be unconscious in 20 min. Clinical features after 
poisoning by other thioate organophosphorus, such as dimethoate and fenthion, happen 
later, giving the patient more time to present to hospital.
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atropine for control of seizures induced by inhaled 
organophosphorus nerve agents.60 However, extra-
pyramidal eﬀ ects and seizures are not common features 
of organophosphorus poisoning.9,21 
Atropine will probably remain the antimuscarinic agent 
of choice until high-quality randomised trials show 
another muscarinic antagonist to have a better 
beneﬁ t-to-harm ratio because it is available widely, 
aﬀ ordable, and moderately able to penetrate into the 
CNS. No known randomised controlled trials have 
compared diﬀ erent regimens of atropine for either 
loading or continuation therapy. As a result, many 
diﬀ erent recommendations have been made—a 
2004 review noted more than 30 dosing regimens, some 
of which would take many hours to give the full loading 
dose of atropine.15 
The aim of early therapy is to reverse cholinergic 
features and to improve cardiac and respiratory function 
as quickly as possible. We use a regimen of doubling 
doses18 (panel 2), with the aim of raising the pulse above 
80 beats per minute and systolic blood pressure above 
80 mm Hg, and rapidly reversing bronchospasm and 
bronchorrhoea. This regimen allows for as much as 
70 mg of atropine to be given in stages to a patient in less 
than 30 min, resulting in rapid stabilisation and low risk 
of atropine toxicity.15 A study from south India61 recorded 
beneﬁ t from an infusion of atropine compared with 
repeated bolus doses, but it used historical controls thus 
reducing conﬁ dence in this ﬁ nding. Infusions could 
reduce ﬂ uctuations in blood atropine concentration, 
reducing the need for frequent patient observation, an 
important beneﬁ t in hospitals with few staﬀ .
Oximes
Oximes reactivate acetylcholinesterase inhibited by 
oganophosphorus.13 Pralidoxime was discovered in the 
mid-1950s by Wilson and colleagues, and was soon 
successfully introduced into clinical practice for patients 
with parathion poisoning.37 Other oximes, such as 
obidoxime and trimedoxime, have been developed but 
pralidoxime remains the most widely used. It has four 
salts: chloride, iodide, metilsulfate, and mesilate.62 The 
chloride and iodide salts are used widely, but metilsulfate 
and mesilate are used mostly in France, Belgium, and 
the UK. The chloride salt has advantages over iodide—in 
particular its smaller molecular weight (173 vs 264), which 
provides 1·5-times more active compound per gram of 
salt than does iodide. High doses of pralidoxime iodide 
also puts patients at risk of thyroid toxicity, especially if 
given for a long period.63
Despite the beneﬁ cial eﬀ ects of pralidoxime ﬁ rst noted 
with parathion poisoning, its eﬀ ectiveness has been 
much debated, with many Asian clinicians unconvinced 
of its beneﬁ t.64–66 In particular, two randomised controlled 
trials in Vellore, India in the early 1990s noted that 
low-dose infusions of pralidoxime might cause harm.67,68 
The absense of clinical beneﬁ t could relate to trial design 
(suboptimum dose, or bias in allocation). Alternatively, 
this result could suggest that pralidoxime is ineﬀ ective in 
the patients seen at this hospital, perhaps because of the 
speciﬁ c pesticide ingested, the amount ingested, or the 
patients’ long delay before pralidoxime is given.69,70
A Cochrane review71 and two other meta-analyses72,73 of 
pralidoxime have been published. The Cochrane review 
included two randomised controlled trials68,69 and reported 
no clear evidence of beneﬁ t or harm. The other 
meta-analyses combined non-randomised or historically 
controlled observational studies64,74–78 with randomised 
controlled trials67,68,79 reducing conﬁ dence80,81 in their 
conclusion that oximes are harmful.
Since these meta-analyses were completed, a randomised 
controlled trial in Baramati, India82 studied the eﬀ ect of 
very-high-dose pralidoxime iodide (2 g loading dose, then 
1 g either every hour or every 4 h for 48 h, then 1 g every 4 h 
until recovery) in 200 patients with moderate 
organophosphorus poisoning (excluding severely ill 
patients). The high-dose regimen was associated with 
reduced case fatality (1% vs 8%; odds ratio [OR] 0·12, 
95% CI 0·003–0·90), fewer cases of pneumonia (8% 
vs 35%; 0·16, 0·06–0·39), and reduced time on mechanical 
ventilation (median 5 days vs 10 days). Laboratory studies 
to identify the pesticide ingested and degree of baseline 
acetylcholinesterase inhibition and subsequent reversal 
were not done.63 However, this study suggests that large 
doses of pralidoxime could have beneﬁ t if patients are 
treated early and have good supportive care.
Observational studies of pralidoxime and obidoxime 
suggest that the ability to reverse acetylcholinesterase 
inhibition with oximes varies with the pesticide ingested 
(ﬁ gure 4).9,13,69,83 Acetylcholinesterase inhibited by diethyl 
pesticides, such as parathion and quinalphos, seems to be 
eﬀ ectively reactivated by oximes, but acetylcholinesterase 
inhibited by dimethyl organophosphorus, such as 
monocrotophos or oxydemeton-methyl, seems to respond 
poorly. We noted that acetylcholinesterase inhibited by 
S-alkyl-linked organophosphorus, such as profenofos, is 
not reactivated by oximes at all (ﬁ gure 4). This diﬀ erence is 
probably partly because of variation in the speed of 
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Figure 3: Chemical classes of organophosphorus pesticides
Structures of organophosphorus pesticides from diethyl (A, B, C), dimethyl (D), and S-alkyl (E,F) classes. Most 
organophosphorus pesticides are thioates, with a double-bonded sulphur atom linked to the phosphate (A, C, F) 
that needs to be converted to the active oxon (eg, A to B). A few organophosphorus pesticides are oxons (eg, D, E) 
and do not need activation; they are able to inhibit acetylcholinesterase directly as soon as they are absorbed.
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acetylcholinesterase ageing (panel 5) induced by these 
diﬀ erent pesticides. Interestingly, the Baramati82 study did 
not ﬁ nd a diﬀ erence in beneﬁ t of high-dose pralidoxime in 
moderate dimethyl or diethyl organophosphorus 
poisoning. Further studies are needed to establish whether 
this beneﬁ t remains for severe poisoning.
Interpretation of clinical evidence regarding oximes 
should take into account this variability in response of 
diﬀ erent pesticides.69 The clinical eﬀ ects can also be 
limited by high concentrations of organophosphorus in 
the blood after ingestion of a large dose—the pesticide 
simply re-inhibits any acetylcholinesterase that the 
oximes reactivate. Oximes will also not be eﬀ ective for 
improvement of outcomes if the patient develops severe 
complications such as aspiration pneumonia or hypoxic 
brain injury before treatment. Such complications take 
place most often with fast-acting pesticides such as 
parathion and dichlorvos.
WHO recommends that oximes be given to all 
symptomatic patients who need atropine.14,84 To ensure 
a therapeutic concentration, a loading dose of 
pralidoxime chloride or obidoxime is given, then a 
continuous infusion. The loading dose of oxime should 
not be given rapidly as a bolus because this method 
causes vomiting (risking aspiration), tachycardia, and 
diastolic hypertension.13
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Figure 4: Variable response to oximes of acetylcholinesterase inhibited by 
diﬀ erent classes of organophosphorus pesticides
Acetylcholinesterase was reactivated fully (A) quinalphos, a diethyl pesticide; 
partially (B) oxydemeton-methyl, a dimethyl pesticide, or not at all 
(C) profenofos, an S-alkyl pesticide by oximes after poisoning. The arrow shows 
the time of ﬁ rst dose of pralidoxime. Normal acetylcholinesterase activity is 
about 600 mU/µmol Hb. In-vitro acetylcholinesterase activity shows how much 
of the enzyme can be reactivated, i.e. how much of it has not yet aged (in these 
three cases, on admission when the ﬁ rst dose of pralidoxime was given, A: ~85%, 
B: ~50%, C: 5%, of the enzyme was not aged). All patients presented to hospital 
within 4 h.
Panel 5: Reactions of acetylcholinesterase after inhibition 
with organophosphorus
Inhibited acetylcholinesterase reactivates spontaneously but 
slowly. The half-life of reactivation varies according to the 
organophosphorus: if dimethyl, the half-life is about 1 h; if 
diethyl, the half-life is around 30 h. Oximes speed up this 
reactivation. Unfortunately, if the organophosphorus is 
present in high concentrations, newly reactivated 
acetylcholinesterase will be rapidly reinhibited. Whether 
reactivation or inhibition predominates depends on the type 
of organophosphorus and relative concentrations and 
aﬃ  nities of organophosphorus and oxime.
Inhibited acetylcholinesterase can also become aged, by loss 
of one of the two alkyl groups attached to the bound 
phosphate. Aged acetylcholinesterase cannot be reactivated 
by oximes. The half-life of ageing varies according to the 
inhibiting pesticide: if dimethyl, the half-life is around 3 h; if 
diethyl, the half-life is around 33 h. Thus ageing has 
important clinical consequences.
If a patient who has ingested a dimethyl pesticide presents to 
hospital 3 h after ingestion, about 50% of the 
acetylcholinesterase will already be aged and unresponsive to 
oximes. A patient arriving after 12 h will have about 94% 
aged acetylcholinesterase and therefore be unresponsive to 
oximes. Such a situation is common where patients need to 
be transferred to a secondary hospital to receive oximes. The 
situation is better with diethyl pesticides since it takes 33 h 
for 50% inhibition and oximes can be eﬀ ective for up to 
5 days after ingestion.
Ageing seems to take place much more quickly after 
poisoning with atypical organophosphorus, such as 
profenofos, that have neither two methyl groups nor two 
ethyl groups (ﬁ gure 3). The half-life of ageing seems to be 
much less than 1 h, thus oximes are completely ineﬀ ective if 
the patient presents more than an hour or two after 
ingestion (ﬁ gure 4).
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Benzodiazepines
Patients poisoned with organophosphorus frequently 
develop agitated delirium. The cause is complex, with 
contributions from the pesticide itself, atropine toxicity, 
hypoxia, alcohol ingested with the poison, and medical 
complications. Although the mainstay of management is 
prevention or treatment of underlying causes, some 
patients need pharmacotherapy. Acutely agitated patients 
will beneﬁ t from treatment with diazepam. 
Diazepam is ﬁ rst-line therapy for seizures; however, 
seizures are uncommon in well oxygenated patients with 
pesticide poisoning.9,48 Seizures seem to be more common 
with organophosphorus nerve agents (such as soman 
and tabun).85 Animal studies suggest that diazepam 
reduces neural damage86 and prevents respiratory failure 
and death,87 but studies in humans are few.
Gastrointestinal decontamination
Gastric lavage is often the ﬁ rst intervention poisoned 
patients receive on presentation to hospital, sometimes 
at the expense of resuscitation and giving antidote.88 No 
evidence shows any form of gastric decontamination to 
beneﬁ t patients poisoned with organophosphorus.35 
Gastric decontamination should only be done after the 
patient has been stabilised and treated with oxygen, 
atropine, and an oxime.88
Gastric lavage is the most common form of 
decontamination for organophosphorus poisoning despite 
the absence of randomised controlled trials to conﬁ rm 
beneﬁ t.35 The rate of absorption of organo phosphorus 
from the human bowel is not known; however, with some 
pesticides, the rapid onset of poisoning in animals89 and 
humans39 suggests that absorption is rapid, occurring 
within minutes of ingestion. The time window for eﬀ ective 
lavage is therefore probably short. Guidelines for treatment 
of drug self-poisoning suggest that lavage should be 
considered only if the patient arrives within 1 hour of 
ingesting poison.90 The relevance of these guidelines to 
organophosphorus poisoning is unclear91 but lavage 
should probably only be considered for patients who 
present soon after ingestion of a substantial amount of 
toxic pesticide who are intubated, or conscious and willing 
to cooperate. Repeated gastric lavages are recommended 
in China to remove pesticide remaining in the stomach,92 
although substantial amounts of organophosphorus are 
unlikely to remain in the stomach after one lavage.
Ipecacuanha-induced emesis should not be used in 
organo phosphorus pesticide poisoning.35,93 Patients 
poisoned with organophosphorus can rapidly become 
unconscious, risking aspiration if ipecacuanha has been 
given. Mechanically-induced emesis with large quantities 
of water risks pushing ﬂ uid through the pylorus and into 
the small bowel, probably increasing the rate of 
absorption.93
A randomised controlled trial of single and multiple 
doses of superactivated charcoal in Sri Lanka failed to 
ﬁ nd a signiﬁ cant beneﬁ t of either regimen over placebo 
in more than 1000 patients poisoned with pesticides.94 
Because activated charcoal binds organophosphorus in 
vitro,95 the absence of eﬀ ect in patients might be due to 
rapid absorption of pesticide into the blood. Alternatively, 
the ingested dose in fatal cases could be too large for the 
amount of charcoal given, the charcoal might be given 
too late, or the solvent might interfere with binding. No 
evidence suggests that patients with pesticide poisoning 
beneﬁ t from treatment with activated charcoal.
Other therapies
Current therapy works through only a few mechanisms.96 
Several new therapies have been studied but results were 
inconclusive. However, future research might reveal 
several aﬀ ordable therapies working at separate sites that 
could complement present treatments. 
Magnesium sulphate blocks ligand-gated calcium 
channels, resulting in reduced acetylcholine release from 
pre-synaptic terminals, thus improving function at 
neuromuscular junctions, and reduced CNS over-
stimulation mediated via NMDA receptor activation.97 A 
trial in people poisoned with organophosphorus pesticides 
recorded reduced mortality with magnesium sulphate 
(0/11 [0%] vs 5/34 [14·7%]; p<0·01).98 However, the study 
was small, allocation was not randomised (every fourth 
patient received the intervention), and the publication 
incompletely described the dose of magnesium sulphate 
used and other aspects of the methodology; therefore these 
results should be interpreted with caution.
The alpha2-adrenergic receptor agonist clonidine also 
reduces acetylcholine synthesis and release from 
presynaptic terminals. Animal studies show beneﬁ t of 
clonidine treatment, especially in combination with 
atropine, but eﬀ ects in human beings are unknown.99
Sodium bicarbonate is sometimes used for treatment 
of organophosphorus poisoning in Brazil and Iran, in 
place of oximes.100,101 Increases in blood pH (up to 7·45– 
7·55) have been reported to improve outcome in dogs 
through an unknown mechanism;102 however, a Cochrane 
review103 concluded that insuﬃ  cient evidence exists at 
present to establish whether sodium bicarbonate should 
be used in humans poisoned with organophosphorus. 
Removing organophosphorus from the blood could 
allow optimum action of other therapies. The roles of 
haemodialysis and haemoﬁ ltration are not yet clear; 
however, a recent non-randomised controlled study in 
China104 suggested a beneﬁ t of haemoﬁ ltration after 
poisoning with dichlorvos, which has poor solubility in 
fat, and therefore should have a relatively small volume 
of distribution. A systematic review of these therapies in 
organophosphorus poisoning is underway, but 
randomised controlled trials will be needed to establish 
good evidence-based treatment guidelines.
Butyrylcholinesterase scavenges organophosphorus in 
plasma, reducing the amount available to inhibit 
acetylcholinesterase in synapses.105 It has been cloned 
and military research now aims to inject soldiers with the 
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enzyme before exposure to organophosphorus nerve 
gases.106 Such a prophylactic approach is not practical for 
self-poisoning with organophosphorus because we 
cannot predict when a person is going to ingest the 
pesticide. Turkish doctors107 have reported the use of 
butyrylcholinesterase in fresh frozen plasma to treat 
poisoned patients. A small controlled study (12 patients 
given fresh frozen plasma with 21 control patients) 
recorded beneﬁ t, but this trial was not randomised and 
allocation decisions were unclear. 
Furthermore, whether or not scavenging of 
organophosphorus by butyrylcholinesterase is the 
mechanism for any eﬀ ect of fresh frozen plasma is 
unclear.108 In fact, butylcholinesterase seems unlikely to 
ever be an eﬀ ective treatment for pesticide poisoning since 
it binds stoichiometrically to organophosphorus and will 
be overpowered by the amount of pesticide commonly 
ingested. For example, 50 mL of 40% dimethoate 
(molecular weight 229) contains 20 g or 87·3 mmol of 
organophosphorous, which, if completely absorbed and 
transformed into the oxon, would need an equivalent 
number of moles of butyrylcholinesterase (molecular 
weight about 70 kD; therefore 6 kg) for inactivation. 
A better approach than use of butylcholinesterase might 
be to give recombinant bacterial phospho triesterases, or 
hydro lases.109,110 These proteins break down organo phos-
phorus pesticides enzymatically and protect animals from 
pesti cide poisoning. Future clinical development of such 
enzymes could reduce blood concentrations of organo phos-
phorus, allowing optimum activity of other treatments.
Conclusion
Medical management of organophosphorus pesticide 
poisoning is diﬃ  cult, especially in resource poor locations 
where most of these patients present. Clinical practice is 
frequently less than ideal, with poor initial resuscitation 
and stabilisation, and poor use of antidotes. However, most 
of the original research regarding acute organophosphorus 
poisoning in humans has been published in the past 
decade, which is a positive development. We expect that in 
the next decade evidence from continuing research by a 
number of groups across Asia will ﬁ nally provide clear 
guidance on how to treat poisoning with organophosphorus 
pesticides. Hopefully, this new guidance will include the 
use of novel antidotes that will reduce the case fatality from 
pesticide poisoning, and therefore reduce the worldwide 
number of deaths from self-harm.
Contributors
ME wrote the ﬁ rst draft of this manuscript after detailed discussion with 
the other authors. All authors contributed to draft revisions and 
approved the ﬁ nal version.
Conﬂ ict of interest statement
The authors do not have any ﬁ nancial conﬂ icts of interest associated 
with writing this review. They have been funded to do observational 
studies, systematic reviews, and randomised controlled trials of 
interventions for organophosphorus pesticide poisoning in Sri Lanka 
over the past 4 years. The results of these studies are cited in this review. 
ME is a Wellcome Trust Career Development Fellow.
Acknowledgments
We thank Lewis Nelson, Yi Li, Nick Bateman, Geoﬀ  Isbister, and the 
Lancet reviewers for their comments on the manuscript and members 
of the Ox-Col study team and the South Asian Clinical Toxicology 
Research Collaboration for their work in Sri Lanka. We thank 
Dr F Worek and Dr H Thiermann of the Bundeswehr Institute of 
Pharmacology and Toxicology for their support of the research in Sri 
Lanka. This work was funded by a grant to ME (063560MA) from the 
Wellcome Trust’s Tropical Interest Group. The South Asian Clinical 
Toxicology Research Collaboration (SACTRC) is funded by the 
Wellcome Trust and Australian National Health and Medical Research 
Council International Collaborative Research Grant 071669MA. 
References 
1 Jeyaratnam J. Acute pesticide poisoning: a major global health 
problem. World Health Stat Q 1990; 43: 139–44.
2 van der Hoek W, Konradsen F, Athukorala K, Wanigadewa T. 
Pesticide poisoning: a major health problem in Sri Lanka. 
Soc Sci Med 1998; 46: 495–504.
3  Eddleston M, Phillips MR. Self poisoning with pesticides. BMJ 
2004; 328: 42–4.
4 World Health Organization. World Health Report 2002. Reducing 
risks, promoting healthy life. Geneva, World Health Organization, 
2002.
5 Eddleston M. Patterns and problems of deliberate self-poisoning in 
the developing world. Q J Med 2000; 93: 715–31.
6 WHO. Public health impact of pesticides used in agriculture. 
Geneva: World Health Organization, 1990.
7 McConnell R, Hruska AJ. An epidemic of pesticide poisoning in 
Nicaragua: implications for prevention in developing countries. 
Am J Public Health 1993; 83: 1559–62.
8  Rosenthal E. The tragedy of Tauccamarca: a human rights 
perspective on the pesticide poisoning deaths of 4 children in the 
Peruvian Andes. Int J Occup Environ Health 2003; 9: 53–58.
9 Eddleston M, Eyer P, Worek F, et al. Diﬀ erences between 
organophosphorus insecticides in human self-poisoning: a 
prospective cohort study. Lancet 2005; 366: 1452–59.
10 Eddleston M, Gunnell D, Karunaratne A, De Silva D, Sheriﬀ  MHR, 
Buckley NA. Epidemiology of intentional self-poisoning in rural 
Sri Lanka. Br J Psychiatry 2005; 187: 583–84.
11 Srinivas Rao CH, Venkateswarlu V, Surender T, Eddleston M, 
Buckley NA. Insecticide poisoning in south India—opportunities 
for prevention and improved medical management. 
Trop Med Int Health 2005; 10: 581–88.
12 Buckley NA, Karalliedde L, Dawson A, Senanayake N, Eddleston M. 
Where is the evidence for the management of pesticide poisoning—
is clinical toxicology ﬁ ddling while the developing world burns? 
J Toxicol Clin Toxicol 2004; 42: 113–16.
13 Eyer P. The role of oximes in the management of 
organophosphorus pesticide poisoning. Toxicol Rev 2003; 22: 
165–90.
14 Johnson MK, Jacobsen D, Meredith TJ, et al. Evaluation of antidotes 
for poisoning by organophosphorus pesticides. Emerg Med 2000; 12: 
22–37.
15 Eddleston M, Buckley NA, Checketts H, et al. Speed of initial 
atropinisation in signiﬁ cant organophosphorus pesticide 
poisoning—a systematic comparison of recommended regimens. 
J Toxicol Clin Toxicol 2004; 42: 865–75.
16 Eddleston M, Karalliedde L, Buckley N, et al. Pesticide poisoning in 
the developing world—a minimum pesticides list. Lancet 2002; 360: 
1163–67.
17 Lotti M. Clinical toxicology of anticholinesterase agents in humans. 
In: Krieger R, ed. Handbook of pesticide toxicology. Volume 2. 
Agents, 2 edn. San Diego: Academic Press, 2001: 1043–85.
18 Aaron CK. Organophosphates and carbamates. In: Ford MD, 
Delaney KA, Ling LJ, Erickson T, eds. Clinical toxicology. 
Philadelphia: WB Saunders Company, 2001: 819–28. 
19 Erdman AR. Insecticides. In: Dart RC, Caravati EM, McGuigan MA, 
et al, eds. Medical toxicology, 3rd edn. Philadelphia: Lippincott 
Williams & Wilkins, 2004: 1475–96. 
20 Clark RF. Insecticides: organic phosphorus compounds and 
carbamates. In: Goldfrank’s Toxicological Emergencies, 7th edn. 
New York: McGraw-Hill Professional, 2002: 1346–60.
Review
606 www.thelancet.com   Vol 371   February 16, 2008 
21 Wadia RS, Sadagopan C, Amin RB, Sardesai HV. Neurological 
manifestations of organophosphate insecticide poisoning. 
J Neurol Neurosurg Psych 1974; 37: 841–47.
22 Senanayake N, Karalliedde L. Neurotoxic eﬀ ects of 
organophosphate insecticides: an intermediate syndrome. 
N Engl J Med 1987; 316: 761–63.
23 Worek F, Mast U, Kiderlen D, Diepold C, Eyer P. Improved 
determination of acetylcholinesterase activity in human whole 
blood. Clin Chim Acta 1999; 288: 73–90.
24 Mason HJ. The recovery of plasma cholinesterase and erythrocyte 
acetylcholinesterase activity in workers after over-exposure to 
dichlorvos. Occup Med (London) 2000; 50: 343–47.
25 Whittaker M. Cholinesterases. In: Bergmeyer HU, ed. Methods of 
enzymatic analysis volume 4. Weinheim, Verlag Chemie, 1984: 52–74. 
26 Reiner E, Buntic A, Trdak M, Simeon V. Eﬀ ect of temperature on the 
activity of human blood cholinesterases. Arch Toxicol 1974; 32: 347–50.
27 Li B, Sedlacek M, Manoharan I, et al. Butyrylcholinesterase, 
paraoxonase, and albumin esterase, but not carboxylesterase, are 
present in human plasma. Biochem Pharmacol 2005; 70: 1673–84.
28 Worek F, Eyer P. The liberation of thiocholine from acetylthiocholine 
(ASCh) by pralidoxime iodide (2=PAM) and other oximes (obidoxime 
and diacetylmonoxime). Toxicol Lett 2006; 167: 256–57.
29 Thiermann H, Worek F, Szinicz L, et al. On the atropine demand 
in organophosphate poisoned patients. J Toxicol Clin Toxicol 2003; 
41: 457.
30 Thiermann H, Szinicz L, Eyer P, Zilker T, Worek F. Correlation 
between red blood cell acetylcholinesterase activity and 
neuromuscular transmission in organophosphate poisoning. 
Chem Biol Interact 2005; 157–58: 345–47.
31 Eddleston M, Dawson A, Karalliedde L, et al. Early management after 
self-poisoning with an organophosphorus or carbamate pesticide—
a treatment protocol for junior doctors. Crit Care 2004; 8: R391–R397.
32 Aaron CK. Organophosphates and carbamates. In: Shannon MS, 
Borron SW, Burns M, eds. Clinical management of poisoning and 
drug overdose, 4th edn. New York, Elsevier Science, 2006.
33 Buckley NA, Dawson AH, Whyte IM. Organophosphate poisoning. 
Peripheral vascular resistance—a measure of adequate 
atropinization. J Toxicol Clin Toxicol 1994; 32: 61–68.
34 Asari Y, Kamijyo Y, Soma K. Changes in the hemodynamic state of 
patients with acute lethal organophosphate poisoning. 
Vet Hum Toxicol 2004; 46: 5–9.
35 Eddleston M, Singh S, Buckley N. Organophosphorus poisoning 
(acute). Clin Evid 2005; 13: 1744–55.
36 Freeman G, Epstein MA. Therapeutic factors in survival after lethal 
cholinesterase inhibition by phosphorus pesticides. N Engl J Med 
1955; 253: 266–71.
37 Namba T, Hiraki K. PAM (pyridine-2-aldoxime methiodide) therapy 
of alkylphosphate poisoning. JAMA 1958; 166: 1834–39.
38 Zilker T, Hibler A. Treatment of severe parathion poisoning. In: 
Szinicz L, Eyer P, Klimmek R, eds. Role of oximes in the treatment 
of anticholinesterase agent poisoning. Heidelberg: Spektrum, 
Akademischer Verlag, 1996: 9–17. 
39 Eyer F, Meischner V, Kiderlen D, et al. Human parathion poisoning. 
A toxicokinetic analysis. Toxicol Rev 2003; 22: 143–63.
40 WHO. WHO recommended classiﬁ cation of pesticides by hazard and 
guidelines to classiﬁ cation 2000–2001. WHO/PCS/01.4. Geneva: 
World Health Organization, 2001.
41 Baker EL, Warren M, Zack M, et al. Epidemic malathion poisoning 
in Pakistan malaria workers. Lancet 1978; 1: 31–4.
42 Aldridge WN, Miles JW, Mount DL, Verschoyle RD. The toxicological 
properties of impurities in malathion. Arch Toxicol 1979; 42: 95–106.
43 Soliman SA, Sovocool GW, Curley A, Ahmed NS, El-Fiki S, 
El-Sebae SK. Two acute human poisoning cases resulting from 
exposure to diazinon transformation products in Egypt. 
Arch Environ Health 1982; 37: 207–12.
44 Meleney WP, Peterson HO. The relationship of shelf age to toxicity 
of dimethoate to sheep. J Am Vet Med Assoc 1964; 144: 756–58.
45 Buratti FM, Volpe MT, Fabrizi L, Meneguz A, Vittozzi L, Testai E. 
Kinetic parameters of OPT pesticide desulfuration by c-DNA 
expressed human CYPs. Environ Toxicol Pharmacol 2002; 11: 181–90.
46 Buratti FM, Volpe MT, Meneguz A, Vittozzi L, Testai E. CYP-speciﬁ c 
bioactivation of four organophosphorothioate pesticides by human 
liver microsomes. Toxicol Appl Pharmacol 2003; 186: 143–54.
47 Benfenati E, Gini G, Piclin N, Roncaglioni A, Vari MR. Predicting log P 
of pesticides using diﬀ erent software. Chemosphere 2003; 53: 1155–64.
48 Wadia RS, Bhirud RH, Gulavani AV, Amin RB. Neurological 
manifestations of three organophosphate poisons. Indian J Med Res 
1977; 66: 460–68.
49 Heath AJW, Meredith T. Atropine in the management of 
anticholinesterase poisoning. In: Ballantyne B, Marrs T, eds. Clinical 
and experimental toxicology of organophosphates and carbamates. 
Oxford: Butterworth Heinemann, 1992: 543–54. 
50 Reigart JR, Roberts JR. Organophosphate insecticides. In: 
Recognition and management of pesticide poisonings, 5th edn. 
Washington DC, Oﬃ  ce of Pesticide Programs, US Environmental 
Protection Agency, 1999: 34–47.
51 Vance MV, Selden BS, Clark RF. Optimal patient position for 
transport and initial management of toxic ingestions. 
Ann Emerg Med 1992; 21: 243–46.
52 Anvari M, Horowitz M, Fraser R, et al. Eﬀ ects of posture on gastric 
emptying of nonnutrient liquids and antropyloroduodenal motility. 
Am J Physiol 1995; 268 (5 Pt 1): G868–71.
53 Geller RJ, Singleton KL, Tarantino ML. Nosocomial poisoning 
associated with emergency department treatment of 
organophosphate toxicity—Georgia, 2000. 
MMWR Morb Mortal Wkly Rep 2001; 49: 1156–58.
54 Stacey R, Morfey D, Payne S. Secondary contamination in 
organophosphate poisoning: analysis of an incident. Q J Med 2004; 
97: 75–80.
55 Little M, Murray L. Consensus statement: Risk of nosocomial 
organophosphate poisoning in emergency departments. 
Emerg Med Australasia 2004; 16: 456–58.
56 Roberts D, Senarathna L. Secondary contamination in 
organophosphate poisoning. Q J Med 2004; 97: 697–98.
57 Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. 
In: Hardman JG, Limbird LE, eds. Goodman and Gilman’s The 
pharmacological basis of therapeutics, 10th edn. New York: 
McGraw-Hill, 2001: 155–73.
58 Bardin PG, van Eeden SF. Organophosphate poisoning: grading the 
severity and comparing treatment between atropine and 
glycopyrrolate. Crit Care Med 1990; 18: 956–60.
59 Kventsel I, Berkovitch M, Reiss A, Bulkowstein M, Kozer E. 
Scopolamine treatment for severe extra-pyramidal signs following 
organophosphate (chlorpyrifos) ingestion. Clin Toxicol 2005; 43: 
877–79.
60 McDonough JH, Zoeﬀ el LD, McMonagle J, Copeland TL, 
Smith CD, Shih TM. Anticonvulsant treatment of nerve agent 
seizures: anticholinergics versus diazepam in soman-intoxicated 
guinea pigs. Epilepsy Res 2000; 38: 1–14.
61 Sunder Ram J, Kumar SS, Jayarajan A, Kuppuswamy G. 
Continuous infusion of high doses of atropine in the management 
of organophosphorus compound poisoning. J Assoc Physicians India 
1991; 39: 190–93.
62 Bismuth C, Inns RH, Marrs TC. Eﬃ  cacy, toxicity and clinical uses 
of oximes in anticholinesterase poisoning. In: Ballantyne B, Marrs 
T, eds. Clinical and experimental toxicology of organophosphates 
and carbamates. Oxford: Butterworth Heinemann, 1992: 555–77. 
63 Eyer P, Buckley NA. Pralidoxime for organophosphate poisoning. 
Lancet 2006; 368: 2110–11.
64 de Silva HJ, Wijewickrema R, Senanayake N. Does pralidoxime 
aﬀ ect outcome of management in acute organophosphate 
poisoning? Lancet 1992; 339: 1136–38.
65 Singh S, Batra YK, Singh SM, Wig N, Sharma BK. Is atropine alone 
suﬃ  cient in acute severe organophosphate poisoning? Experience 
of a North West Indian hospital. Int J Clin Pharmacol Ther 1995; 33: 
628–30.
66 Peter JV, Cherian AM. Organic insecticides. Anaesth Intens Care 
2000; 28: 11–21.
67 Johnson S, Peter JV, Thomas K, Jeyaseelan L, Cherian AM. Evaluation 
of two treatment regimens of pralidoxime (1 gm single bolus dose vs 
12 gm infusion) in the management of organophosphorus poisoning. 
J Assoc Physicians India 1996; 44: 529–31.
68 Cherian AM, Peter JV, Samuel J, et al. Eﬀ ectiveness of P2AM (PAM 
-pralidoxime) in the treatment of organophosphorus poisoning. A 
randomised, double blind placebo controlled trial. 
J Assoc Physicians India 1997; 45: 22–24.
Review
www.thelancet.com   Vol 371   February 16, 2008 607
69 Eddleston M, Szinicz L, Eyer P, Buckley N. Oximes in acute 
organophosphorus pesticide poisoning: a systematic review of 
clinical trials. Q J Med 2002; 95: 275–83.
70 Peter JV, Moran JL. Role of oximes in human organophosphate 
poisoning—a critical look at the evidence. In: Nayyar V, ed. Critical 
Care Update 2004. New Delhi: Jaypee, 2004: 153–63. 
71 Buckley NA, Eddleston M, Szinicz L. Oximes for acute 
organophosphate pesticide poisoning. Cochrane Database Syst Rev 
2005; 1: CD005085.
72 Peter JV, Moran JL, Graham P. Oxime therapy and outcomes in 
human organophosphate poisoning: an evaluation using 
meta-analytic techniques. Crit Care Med 2006; 34: 502–10.
73 Rahimi R, Nikfar S, Abdollahi M. Increased morbidity and mortality 
in acute human organophosphate-poisoned patients treated by 
oximes: a meta-analysis of clinical trials. Hum Exp Toxicol 2006; 25: 
157–62.
74 Duval G, Rakouer JM, Tillant D, Auﬀ ray JC, Nigond J, Deluvallee G. 
Intoxications aiguës par insecticides à action anticholinestérasique. 
Evaluation de l’eﬃ  cacité d’un réactivateur des cholinestérases, le 
pralidoxime. J Toxicol Clin Exp 1991; 11: 51–58.
75 Abdollahi M, Jafari A, Jalali N, Balali-Mood M, Kebriaeezadeh A, 
Nikfar S. A new approach to the eﬃ  cacy of oximes in the 
management of acute organophosphate poisoning. 
Iranian J Med Sci 1995; 20: 105–09.
76 Balali-Mood M, Shariat M. Treatment of organophosphate 
poisoning. Experience of nerve agents and acute pesticide 
poisoning on the eﬀ ects of oximes. J Physiol (Paris) 1998; 92: 
375–78.
77 Sungur M, Guven M. Intensive care management of 
organophosphate insecticide poisoning. Crit Care 2001; 5: 211–15.
78 Chugh SN, Aggarwal N, Dabla S, Chhabra B. Comparative 
evaluation of atropine alone and atropine with pralidoxime (PAM) 
in the management of organophosphorus poisoning. 
J Indian Acad Clin Med 2005; 6: 33–37.
79 Cherian MA, Roshini C, Visalakshi J, Jeyaseelan L, Cherian AM. 
Biochemical and clinical proﬁ le after organophosphorus 
poisoning—a placebo-controlled trial using pralidoxime. 
J Assoc Physicians India 2005; 53: 427–31.
80 Grimes DA, Schulz KF. An overview of clinical research: the lay of 
the land. Lancet 2002; 359: 57–61.
81 Grimes DA, Schulz KF. Bias and causal associations in 
observational research. Lancet 2002; 359: 248–52.
82 Pawar KS, Bhoite RR, Pillay CP, Chavan SC, Malshikare DS, Garad 
SG. Continuous pralidoxime infusion versus repeated bolus 
injection to treat organophosphorus pesticide poisoning: a 
randomised controlled trial. Lancet 2006; 368: 2136–41.
83 Thiermann H, Szinicz L, Eyer F, et al. Modern strategies in therapy 
of organophosphate poisoning. Toxicol Lett 1999; 107: 233–39.
84 WHO International Programme on Chemical Safety. Poisons 
information monograph G001. Organophosphorus pesticides. 
Geneva: World Health Organization, 1999.
85 Sidell FR. Nerve agents. In: Sidell FR, Takafuji ET, Franz DR, eds. 
Medical aspects of chemical and biological warfare. Washington, 
DC: Borden Institute, Walter Reed Army Medical Center, 2006: 
129–79. 
86 Murphy MR, Blick DW, Dunn MA. Diazepam as a treatment for 
nerve agent poisoning in primates. Aviat Space Environ Med 1993; 
64: 110–15.
87 Dickson EW, Bird SB, Gaspari RJ, Boyer EW, Ferris CF. Diazepam 
inhibits organophosphate-induced central respiratory depression. 
Acad Emerg Med 2003; 10: 1303–06.
88 Eddleston M, Haggalla S, Reginald K, et al. The hazards of gastric 
lavage for intentional self-poisoning in a resource poor location. 
ClinToxicol 2007; 45: 136–43
89 Kramer RE, Ho IK. Pharmacokinetics and pharmacodynamics of 
methyl parathion. Chinese Med J (Taipei) 2002; 65: 187–99.
90 American Academy of Clinical Toxicology and European 
Association of Poison Centres and Clinical Toxicologists. Position 
paper: gastric lavage. J Toxicol Clin Toxicol 2004; 42: 933–43.
91 Bhattarai MD. Gastric lavage is perhaps more important in 
developing countries. BMJ 2000; 320: 711.
92 Gu YL, Wan WG, Xu ML, Zou HJ. Gastric lavage for 
organophosphate pesticide poisoned patients [in Chinese]. 
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2004; 22: 388–90.
93 American Academy of Clinical Toxicology and European 
Association of Poisons Centres and Clinical Toxicologists. Position 
paper: ipecac syrup. J Toxicol Clin Toxicol 2004; 42: 133 43.
94 Eddleston M, Juszczak E, Buckley NA, et al. Randomised controlled 
trial of routine single or multiple dose superactivated charcoal for 
self-poisoning in a region with high mortality. Clin Toxicol 2005; 43: 
442–43.
95 Guven H, Tuncok Y, Gidener S, et al. In vitro adsorption of 
dichlorvos and parathion by activated charcoal. J Toxicol Clin Toxicol 
1994; 32: 157–63.
96 Buckley NA, Roberts DM, Eddleston M. Overcoming apathy in 
research on organophosphate poisoning. BMJ 2004; 329: 1231–33.
97 Singh G, Avasthi G, Khurana D, Whig J, Mahajan R. 
Neurophysiological monitoring of pharmacological manipulation in 
acute organophosphate poisoning. The eﬀ ects of pralidoxime, 
magnesium sulphate and pancuronium. 
Electroencephalogr Clin Neurophysiol 1998; 107: 140–48.
98 Pajoumand A, Shadnia A, Rezaie A, Abdi M, Abdollahi M. Beneﬁ ts of 
magnesium sulfate in the management of acute human poisoning by 
organophosphorus insecticides. Hum Exp Toxicol 2004; 23: 565–69.
99 Liu WF. A symptomatological assessment of 
organophosphate-induced lethality in mice: comparison of atropine 
and clonidine protection. Toxicol Lett 1991; 56: 19–32.
100 Wong A, Sandron CA, Magalhaes AS, Rocha LCS. Comparative 
eﬃ  cacy of pralidoxime vs sodium bicarbonate in rats and humans 
severely poisoned with O-P pesticide. J Toxicol Clin Toxicol 2000; 38: 
554–55.
101 Balali-Mood M, Ayati MH, Ali-Akbarian H. Eﬀ ect of high doses of 
sodium bicarbonate in acute organophosphorous pesticide 
poisoning. Clin Toxicol 2005; 43: 571–74.
102 Cordoba D, Cadavid S, Angulo D, Ramos I. Organophosphate 
poisoning—modication of acid-base equilibrium and use of sodium 
bicarbonate as an aid in the treatment of toxicity in dogs. 
Vet Hum Toxicol 1983; 25: 1–3.
103 Roberts D, Buckley NA. Alkalinisation for organophosphorus 
pesticide poisoning. Cochrane Database Syst Rev 2005; 1: CD004897.
104 Peng A, Meng FQ, Sun LF, Ji Z-S, Li YH. Therapeutic eﬃ  cacy of 
charcoal hemoperfusion in patients with acute severe dichlorvos 
poisoning. Acta Pharmacol Sin 2004; 25: 15–21.
105 Chambers JE, Oppenheimer SF. Organophosphates, serine esterase 
inhibition, and modeling of organophosphate toxicity. Toxicol Sci 
2004; 77: 185–87.
106 Rosenberg Y, Luo C, Ashani Y, et al. Pharmacokinetics and 
immunologic consequences of exposing macaques to puriﬁ ed 
homologous butyrylcholinesterase. Life Sci 2002; 72: 125–34.
107 Guven M, Sungur M, Eser B, Sary I, Altuntas F. The eﬀ ects of fresh 
frozen plasma on cholinesterase levels and outcomes in patients with 
organophosphate poisoning. J Toxicol Clin Toxicol 2004; 42: 617–23.
108 Fulton JA, Bouchard NC, Becker ML, Gertz S, Hoﬀ man RS. FFP in 
organophosphate poisoning: what’s the secret ingredient? 
Clin Toxicol 2005; 43: 215.
109 Raushel FM. Bacterial detoxiﬁ cation of organophosphate nerve 
agents. Curr Opin Microbiol 2002; 5: 288–95.
110 Sogorb MA, Vilanova E, Carrera V. Future applications of 
phosphotriesterases in the prophylaxis and treatment of 
organophosporus insecticide and nerve agent poisonings. 
Toxicol Lett 2004; 151: 219–33.
